Using our Guardian Angel™ Artificial Intelligence algorithm, we are precisely matching drugs to diseases and identifying the best care for individual patients. We have demonstrated the power of Guardian Angel™ by matching more than 90% of the world’s approved drugs to their indications.
AI-driven drug development means we skip long R&D cycles, getting life-saving drugs to patients faster. Current clinical stage drug candidates target multiple orphan disorders including pulmonary sarcoidosis, bronchiolitis obliterans and amyotrophic lateral sclerosis. Additionally, we have a drug candidate for COVID-19 in clinical trials.